Attached files
| file | filename |
|---|---|
| EX-99 - EXHIBIT 99.1 - RESPONSE BIOMEDICAL CORP | rpbif20130301_8kex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
February 26, 2013
RESPONSE BIOMEDICAL CORP.
(Exact name of registrant as specified in its charter)
|
Vancouver, British Columbia, Canada |
000-50571 |
98 -1042523 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
1781 - 75th Avenue W.
Vancouver, British Columbia, Canada V6P 6P2
(Address of principal executive offices, including zip code)
(604) 456-6010
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On February 26, 2013, Response Biomedical Corp. (the “Company”) announced by press release that Mr. Darby L. Darilek has joined the Company on February 25, 2013 as its Director of U.S. Sales. The hire of Mr. Darilek follows a successful U.S. FDA audit, the launch of the RAMP® 200 in the U.S. for use in laboratory settings and the two new U.S based distribution agreements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
|
Description |
|
99.1 |
Press release of Response Biomedical Corp. dated February 26, 2013 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
RESPONSE BIOMEDICAL CORP. | |||
|
By: |
/s/William J. Adams |
||
|
William J. Adams Chief Financial Officer | |||
Date: March 1, 2013
EXHIBIT INDEX
|
Exhibit Number |
|
Description |
|
99.1 |
Press release of Response Biomedical Corp. dated February 26, 2013 |